Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Apr 7;279(1732):1389-95.
doi: 10.1098/rspb.2011.1697. Epub 2011 Oct 12.

Effects of BRCA1 and BRCA2 mutations on female fertility

Affiliations

Effects of BRCA1 and BRCA2 mutations on female fertility

Ken R Smith et al. Proc Biol Sci. .

Abstract

Women with BRCA1/2 mutations have a significantly higher lifetime risk of developing breast or ovarian cancer. We suggest that female mutation carriers may have improved fitness owing to enhanced fertility relative to non-carriers. Here we show that women who are carriers of BRCA1/2 mutations living in natural fertility conditions have excess fertility as well as excess post-reproductive mortality in relation to controls. Individuals who tested positive for BRCA1/2 mutations who linked into multi-generational pedigrees within the Utah Population Database were used to identify putative obligate carriers. We find that women born before 1930 who are mutation carriers have significantly more children than controls and have excess post-reproductive mortality risks. They also have shorter birth intervals and end child-bearing later than controls. For contemporary women tested directly for BRCA1/2 mutations, an era when modern contraceptives are available, differences in fertility and mortality persist but are attenuated. Our findings suggest the need to re-examine the wider role played by BRCA1/2 mutations. Elevated fertility of female mutation carriers indicates that they are more fecund despite their elevated post-reproductive mortality risks.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
(a) Effects of BRCA1/2 mutation status on number of children ever born, based on ordinary least squares (OLS) regression controlling for birth year, age at first birth and number of deceased children (who died by age 5). (b) Effects of BRCA1/2 mutation status on age at first birth (AFB) and age at last birth (ALB), based on OLS regressions controlling for birth year and age at marriage (and AFB for the ALB model). (c) Effects of BRCA1/2 mutation status on first birth interval (FBI) and average birth interval (ABI), based on OLS regressions controlling for birth year and age at first marriage. (d) Survival probabilities past age 45 by BRCA1/2 mutation status for women born before 1930, based on Cox proportional hazard regressions controlling for birth year. Models for women born before 1930 also controlled for LDS status. Dark grey bars or lines denote carrier and light grey bars or lines denote control.

Comment in

References

    1. Botkin J. R., Croyle R. T., Smith K. R., Baty B. J., Lerman C., Goldgar D. E., Ward J. M., Flick B. J., Nash J. E. 1996. A model protocol for evaluating the behavioral and psychosocial effects of BRCA1 testing. J. Natl Cancer Inst. 88, 872–88210.1093/jnci/88.13.872 (doi:10.1093/jnci/88.13.872) - DOI - DOI - PubMed
    1. Easton D. F., Ford D., Bishop D. T. 1995. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 56, 265–271 - PMC - PubMed
    1. Friedman E., et al. 2006. Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast Cancer Res. 8, R15.10.1186/bcr1387 (doi:10.1186/bcr1387) - DOI - DOI - PMC - PubMed
    1. Moslehi R., Singh R., Lessner L., Friedman J. M. 2010. Impact of BRCA mutations on female fertility and offspring sex ratio. Am. J. Hum. Biol. 22, 201–205 - PMC - PubMed
    1. Mai P. L., Chatterjee N., Hartge P., Tucker M., Brody L., Struewing J. P., Wacholder S., Toland A. E. 2009. Potential excess mortality in BRCA1/2 mutation carriers beyond breast, ovarian, prostate, and pancreatic cancers, and melanoma. PLoS ONE 4, e4812.10.1371/journal.pone.0004812 (doi:10.1371/journal.pone.0004812) - DOI - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources